1. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results. Issue 11 (9th September 2018) Authors: Cortes, Jorge E.; Douglas Smith, B.; Wang, Eunice S.; Merchant, Akil; Oehler, Vivian G.; Arellano, Martha; DeAngelo, Daniel J.; Pollyea, Daniel A.; Sekeres, Mikkael A.; Robak, Tadeusz; Ma, Weidong Wendy; Zeremski, Mirjana; Naveed Shaik, M.; Douglas Laird, A.; O'Connell, Ashleigh; Chan, Geoffrey; ... Journal: American journal of hematology Issue: Volume 93:Issue 11(2018:Nov.) Page Start: 1301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗